SCHEMBL403265

SCHEMBL403265

O=C(O)c1ccc2c(=O)[nH]c(CCCc3ccccn3)nc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
RECQL P46063 1/20 0.59
POLB P06746 2/20 0.54
GLA P06280 1/20 0.54
MAPT P10636 1/20 0.54
PDE5A O76074 1/20 0.53
PARP1 P09874 7/20 0.47
PARP2 Q9UGN5 2/20 0.47
CSNK2A1 P68400 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
TNKS O95271 1/20 0.45
PARP3 Q9Y6F1 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
TP53 P04637 1/20 0.43
G6PD P11413 1/20 0.43
HCAR2 Q8TDS4 2/20 0.43
PDE10A Q9Y233 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401559 0.93 KDM4E (0.61) KDM4ERECQLPOLBGLAMAPT
SCHEMBL405814 0.88 KDM4E (0.62) KDM4ERECQLPOLBGLAMAPT
SCHEMBL404924 0.85 KDM4E (0.65) KDM4ERECQLPOLBPDE5APARP1
SCHEMBL27771771 0.82 KDM4E (0.61) KDM4ERECQLPOLBMAPTPDE5A
SCHEMBL439184 0.80 KDM4E (0.68) KDM4ERECQLPOLBMAPTPDE5A
SCHEMBL405224 0.80 F2 (0.54) KDM4ERECQLPOLBGLAMAPT
SCHEMBL400477 0.80 KDM4E (0.58) KDM4ERECQLPOLBPDE5APARP1
SCHEMBL401612 0.78 KDM4E (0.59) KDM4ERECQLPOLBMAPTPDE5A
SCHEMBL405256 0.78 KDM4E (0.56) KDM4ERECQLPOLBMAPTPDE5A
SCHEMBL403178 0.77 PDE5A (0.78) KDM4ERECQLPOLBPDE5APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD KDM4E 4291/4885RECQL 878/4885POLB 555/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A KDM4E 2869/4885RECQL 100/4885POLB 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.